Gland Pharma Share News - Latest Updates, Live News & More

Latest news about Gland Pharma

Gland Pharma Sees Rs. 45.99 Crore Block Trade on NSE, Schedules Investor Meetings Sep 09, 2025

Gland Pharma experienced a significant block trade on NSE worth Rs. 45.99 crores, involving 240,922 shares at Rs. 1909.00 per share. The company has announced upcoming meetings with analysts and institutional investors, including a one-on-one meeting with Fidelity International on September 11, 2025, and a group meeting at Ambit Capital Investec GuruSpeek 2.0 on September 12, 2025. These developments highlight the ongoing interest in Gland Pharma within the investment community.

Gland Pharma May Benefit from Potential GST Exclusion for Cancer Drugs Sep 03, 2025

Gland Pharma Secures USFDA Approval for Vasopressin Injection, Targeting $45 Million Market Aug 26, 2025

Gland Pharma Secures USFDA Approvals for Cangrelor and Norepinephrine Bitartrate Injections Aug 12, 2025

Gland Pharma Shares See ₹91.12 Crore Block Trade Amid Strong Q1 Performance Aug 06, 2025

More news about Gland Pharma

05Aug 25

Gland Pharma Reports 50% PAT Growth in Q1; Cenexi Achieves EBITDA Breakeven

Gland Pharma announced strong Q1 results with a 50% year-on-year increase in Profit After Tax (PAT) to ₹2,155.00 million. Revenue from operations grew 7% to ₹15,056.00 million, while EBITDA rose 39% to ₹3,678.00 million. The company's European subsidiary, Cenexi, achieved EBITDA breakeven with 20% revenue growth. Gland's base business saw 3% revenue growth and 22% EBITDA increase. Geographically, Europe and Other Core Markets showed significant growth. The company continued to invest in R&D, launched 12 new molecules in regulated markets, and advanced its product pipeline, including GLP-1 expansion and Ready-to-Use bags development.

05Aug 25

Gland Pharma Reports Strong Q1 Results with 50% PAT Growth

Gland Pharma announced robust Q1 FY24 results with revenue up 7% YoY to ₹15,056 million. PAT surged 50% YoY to ₹2,155 million, while EBITDA grew 39% to ₹3,678 million. The company's base business saw 3% revenue growth, and European subsidiary Cenexi achieved EBITDA breakeven. Geographically, Europe showed strong 29% growth, while the USA remained the largest contributor. The company launched 12 new molecules in regulated markets and plans to expand GLP-1 capacity. Management expressed confidence in the company's strategic priorities and long-term vision.

21Jul 25

Gland Pharma Sees Rs. 71.82 Crore Block Trade on NSE

A significant block trade of Gland Pharma shares occurred on the National Stock Exchange. The transaction involved 358,221 shares traded at Rs. 2,005.00 per share, totaling approximately Rs. 71.82 crore. This large-scale trade has drawn attention from market observers, potentially indicating shifts in institutional holdings or significant investor interest in the pharmaceutical company.

21Jul 25

Brookfield and EQT in Talks to Acquire Gland Pharma from Fosun in Potential ₹25,711 Crore Deal

Brookfield and EQT are in discussions to acquire Gland Pharma from China's Fosun Group. Fosun holds a 51.8% stake valued at ₹17,141.28 crore ($1.9 billion). The deal could reach ₹25,711 crore ($3 billion) if a mandatory open offer for an additional 26% stake is triggered. Gland Pharma's rising stock price, up 16% in the past month, complicates negotiations. The company, specializing in generic injectables, reported revenue of ₹5,616.00 crore and profit of ₹698.00 crore in its latest financial report.

14Jul 25

Gland Pharma's Pashamylaram Facility Secures Danish GMP Compliance Certificate

Gland Pharma's Pashamylaram facility has been awarded a Good Manufacturing Practices (GMP) compliance certificate by the Danish Medicines Agency. This certification validates the facility's adherence to European quality standards, potentially enhancing Gland Pharma's credibility and opening opportunities for market expansion in Europe, particularly in Denmark and countries recognizing Danish approvals. The GMP certification serves as an independent verification of the company's manufacturing processes, assuring product quality to customers and partners.

11Jul 25

Gland Pharma's Pashamylaram Facility Secures GMP Compliance Certificate from Danish Medicines Agency

Gland Pharma has received a Good Manufacturing Practice (GMP) compliance certificate from the Danish Medicines Agency for its Pashamylaram facility. The certification covers aseptically prepared powder for injection, infusion, and inhalation products, and applies to marketing authorizations for manufacturers outside the European Economic Area. This achievement validates the company's manufacturing standards and could potentially open up new opportunities in the European market.

24Jun 25

Gland Pharma Receives EIR from US FDA for Visakhapatnam Facility

Gland Pharma has received an Establishment Inspection Report (EIR) from the US FDA for its JNPC facility in Visakhapatnam. This indicates the successful conclusion of the FDA's inspection, suggesting compliance with good manufacturing practices. The EIR receipt is significant for Gland Pharma, potentially boosting market confidence and ensuring operational continuity in the US market.

05Jun 25

Gland Pharma's Subsidiary Cenexi Faces Regulatory Scrutiny in France

Gland Pharma's subsidiary Cenexi received 11 observations from France's drug regulator ANSM during a GMP inspection at its Fontenay facility. Cenexi submitted a CAPA plan, accepted by ANSM, with improvements to be implemented over 3-12 months. Gland Pharma assures that manufacturing operations at the facility will not be impacted.

05Jun 25

Gland Pharma's French Facility Receives 11 Observations in ANSM Inspection

Gland Pharma's manufacturing facility in Fontenay, France, owned by Cenexi, underwent an inspection by the French National Agency for Medicines and Health Products Safety (ANSM). The inspection resulted in 11 observations. Despite this, Gland Pharma does not anticipate any disruption to its manufacturing activities at the facility. The company is expected to address these observations to ensure compliance with ANSM's requirements.

04Jun 25

Gland Pharma's Cenexi Facility Faces 11 Observations in ANSM Inspection

Gland Pharma's Cenexi facility in Fontenay, France, underwent an inspection by the French National Agency for the Safety of Medicines and Health Products (ANSM), resulting in 11 observations. Despite these findings, manufacturing operations at the facility continue uninterrupted. The company will likely need to develop and implement corrective action plans to address the observations.

04Jun 25

Gland Pharma Secures FDA Approval for Generic Blood Pressure Drug, Gains Exclusive Market Access

Gland Pharma has received USFDA approval for its generic Angiotensin II Acetate injection, equivalent to GIAPREZA. The drug, used to treat blood pressure in adults with septic shock, has secured First-to-File status with 180-day market exclusivity. The US market for this drug is valued at $58.00 million for the year ending March 2025. The approval has positively impacted Gland Pharma's stock performance.

04Jun 25

Gland Pharma Secures Approval for Angiotensin II Acetate Injection

Gland Pharma has received approval for its Angiotensin II Acetate Injection, a medication used in treating cardiovascular conditions in critical care settings. The product has reported US sales of approximately USD 58.00 million, indicating a significant market opportunity. This approval is expected to strengthen Gland Pharma's position in the pharmaceutical market, particularly in the United States, and potentially enhance its competitive edge in the specialty pharmaceutical segment.

21May 25

Gland Pharma's Q4 Results Show Core Weakness, Cenexi Challenges

Gland Pharma's Q4 net profit decreased 2.60% year-over-year to ₹1.87 billion, while revenue fell 7.29% to ₹14.25 billion. The company recommended a final dividend of ₹18 per equity share. Despite current challenges, including increased competition and Cenexi-related issues, the company projects a 20% earnings CAGR over FY25-27, driven by new product launches and improving Cenexi performance.

20May 25

Gland Pharma: Q4 Profit and Revenue Decline, Misses Estimates

Gland Pharma's Q4 results show a 3.10% decrease in net profit to ₹186.50 crore and a 7.30% decline in revenue to ₹1,424.90 crore year-over-year. Despite these declines, the company improved its EBITDA margin to 24.40%. The company launched four new molecules, filed five ANDAs, and received seven regulatory approvals. The board proposed a final dividend of ₹18.00 per equity share. Cenexi, its European subsidiary, showed 8.00% year-over-year revenue growth.

19May 25

Gland Pharma Anticipates Stable Q4 Performance with Marginal Revenue Growth

Gland Pharma is expected to report a stable Q4 FY performance with 0.90% YoY revenue growth to Rs 1,551.73 crore. EBITDA is projected to increase by 5.54% to Rs 376.14 crore, indicating potential margin expansion. Key drivers include US business momentum, new product launches, and Cenexi recovery. Investors will focus on updates regarding China expansion and the complex product pipeline.

30Apr 25

Gland Pharma Secures USFDA Approval for Glaucoma Treatment, Gains Exclusivity

Gland Pharma has received USFDA approval for its ANDA for latanoprostene bunod ophthalmic solution, 0.024%, bioequivalent to Bausch and Lomb's VYZULTA. The drug is used to reduce intraocular pressure in glaucoma or ocular hypertension patients. As the first-to-file applicant, Gland Pharma has secured 180 days of generic drug exclusivity. The product's US sales were $171.00 million for the 12 months ending February 2025.

30Apr 25

Gland Pharma Secures USFDA Approval for Glaucoma Treatment, Eyeing $171 Million Market

Gland Pharma has received USFDA approval for Latanoprostene Bunod Ophthalmic Solution, 0.024%, a treatment for glaucoma and ocular hypertension. The product is bioequivalent to Bausch and Lomb's VYZULTA and had U.S. sales of $171 million in the year ending February 2023. As the exclusive First-to-File applicant, Gland Pharma is eligible for 180 days of generic drug exclusivity. This approval marks a significant expansion of the company's presence in the U.S. ophthalmic market.

16Apr 25

ICICI Prudential MF Boosts Stake in Gland Pharma Amid Stock Price Volatility

ICICI Prudential Mutual Fund increased its stake in Gland Pharma to 5.08% by acquiring 400,020 shares on April 11, 2025. This led to a 0.80% rise in Gland Pharma's stock price to ₹1,439.00, despite a 10% decline in April due to concerns over potential U.S. pharmaceutical tariffs. The institutional investment signals confidence in the company's long-term prospects amidst industry challenges.

03Apr 25

Gland Pharma Secures FDA Approval for Acetaminophen Injection, Tapping into $55 Million US Market

Gland Pharma received USFDA approval for Acetaminophen Injection (10 mg/mL) in 500mg/50mL and 1000mg/100mL bags. The product is bioequivalent to B. Braun Medical's reference drug. The US market for this injection is valued at $55 million annually. Indicated for pain management in adults and children over 2 years, the product will be launched through a marketing partner.

25Feb 25

Gland Pharma's USFDA Inspection at Visakhapatnam Facility Results in Three Observations

Gland Pharma's Visakhapatnam facility underwent a US FDA inspection from February 19-25, 2025, resulting in three Form 483 observations. The company states these are procedural, not repeated, and unrelated to data integrity. Gland Pharma plans to submit corrective actions within the stipulated timeframe. The company also announced upcoming one-on-one meetings with institutional investors on February 27 and 28, 2025.